Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics (NQ: CORT )

41.42 -0.85 (-2.00%)
Streaming Delayed Price Updated: 2:22 PM EDT, Sep 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Corcept Therapeutics

< Previous 1 2 3 Next >
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Completes Enrollment in Phase 4 CATALYST Trial
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Appoints Roberto Vieira as President, Oncology
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Court Finds Corcept Therapeutics’ Patents Not Infringed
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Appoints Monica Tellado as President, Emerging Markets
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH)
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics Inc. (NASDAQ: CORT) Sets New 52-Week High in Wednesday Session
Via Investor Brand Network
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept’s Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH)
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Journal of Clinical Oncology Publishes Results of Corcept’s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics Announces Final Results of Tender Offer
From Corcept Therapeutics Incorporated
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.